2021 / 04

Next Paper
DOI: 10.24075/medet.2021.027

OPINION

Drug repositioning: lessons from the COVID-19 pandemic

Poroykov VV
About authors

Orekhovich Institute of Biomedical Chemistry, Moscow, Russia

Correspondence should be addressed: Vladimir V. Poroikov
Pogodinskaya, ul., 10, Str. 8, Moscow, 119121, Russia; ur.ksm.cmbi@vokiorop.rimidalv

About paper

Acknowledgement: the study is supported by the Ministry of Science and Higher Education of the Russian Federation in the framework of the Interdepartmental Working Group on the Development of Drugs with Direct Antiviral Activity against SARS-CoV-2 (project No. 121102900156–6).

Received: 2021-10-16 Accepted: 2021-11-27 Published online: 2021-12-30
|
  1. Poroikov V, Druzhilovskiy D. Drug repositioning: New opportunities for older drugs. In: In Silico Drug Design, 1st Edition. Repurposing Techniques and Methodologies. Chapter 1. Editor: Kunal Roy. Amsterdam: Elsevier, Academic Press, 2019; 3–17 p.
  2. Muratov EN, Amaro R, Andrade CH, Brown N, Ekins S, Fourches D, Isayev O, Kozakov D, Medina-F ranco J, Merz KM, Oprea TI, Poroikov V, Schneider G, Todd MH, Varnek A, Winkler DA, Zakharov A, Cherkasov A, Tropsha A. A critical overview of computational approaches employed for COVID-19 drug discovery. Chem Soc Rev. 2021; 50 (16): 9121–9151.
  3. Savosina PI, Druzhilovskiy DS, Poroikov VV. COVID-19: Analysis of drug repositioning practice. Pharm Chem J. 2021; 54(10): 989–996.
  4. Mslati H, Gentile F, Perez C, Cherkasov A. Comprehensive consensus analysis of SARS-CoV-2 drug repurposing campaigns. J Chem Inf Model. 2021; 61 (8): 3771–3788.
  5. Gentile F, Agrawal V, Hsing M, Ton AT, Ban F, Norinder U, Gleave ME, Cherkasov A. Deep docking: A deep learning platform for augmentation of structure-b ased drug discovery. ACS Cent Sci. 2020; 6(6): 939–949.
  6. Ionov N, Pogodin P, Poroikov V. Assessing the prediction quality of the anti-S ARS-CoV-2 activity using the D3Targets-2019-nCoV web service. Biomed Chem Res & Meth. 2020; 3(4): е00140.